Company profile
KYVERNA THERAPEUTICS, INC.
NASDAQ:KYTXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MIVOCABTAGENE AUTOLEUCEL | phase2_3 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05938725 | phase1_2 | terminated | 2023-04-28 | 2026-05-29 | Kyverna Therapeutics | KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
| NCT06342960 | phase1_2 | terminated | 2022-12-01 | 2025-12-22 | Kyverna Therapeutics | KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
| NCT06400303 | phase1_2 | terminated | 2024-08-06 | 2026-06-16 | Kyverna Therapeutics | KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis |
| NCT06193889 | phase2_3 | recruiting | 2024-08-28 | 2027-09-01 | Kyverna Therapeutics | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis |
| NCT06384976 | phase2 | active_not_recruiting | 2024-09-20 | 2027-04-01 | Kyverna Therapeutics | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis |
FDA applications (0)
No records yet.